Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$22.95 USD
+0.61 (2.73%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $22.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About Market Cap
As of the previous market close, Apellis Pharmaceuticals, Inc. has a market cap of $2.81B, which represents its share price of $22.34 multiplied by its outstanding shares number of 125.68M. As a mid-cap company, APLS's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
APLS 22.95 +0.61(2.73%)
Will APLS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLS
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say
Repligen (RGEN) Lags Q2 Earnings Estimates
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
Other News for APLS
Apellis price target raised by $4 at JPMorgan, here's why
Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation
Apellis (APLS) Price Target Raised as Market Stabilizes
RBC Capital Raises Price Target for Apellis Pharmaceuticals (APLS) | APLS Stock News